Patient characteristics in medical-pharmacy claims analysis
| Melanoma | Lung cancer | Autoimmune disease | No autoimmune disease | |
| Total patients | 699 | 1321 | 124 | 1896 |
| Average age | 62.6 | 67.0 | 65.4 | 65.5 |
| %Female | 35.1 | 48.9 | 47.6 | 43.9 |
| %Nivolumab | 21.9 | 89.8 | 63.7 | 66.5 |
| %Pembrolizumab | 27.9 | 10.2 | 13.7 | 16.5 |
| %Ipilimumab | 50.2 | N/A | 22.6 | 17.0 |
| %Ipilimumab-nivolumab combo | 7.2 | N/A | 5.7 | 2.3 |
| Median # ICI infusions, PD-1 inhibitors | 2 | 5 | 4 | 4 |
| Median # ICI Infusions, Ipilimumab | 1 | N/A | 1 | 1 |
ICI, immune checkpoint inhibitors.